To The Moon

$Merck(MRK)$ is set to report its fiscal second-quarter 2026 financial results on Tuesday, August 4, 2026, before the market opens (with the investor call scheduled for 9:00 AM ET).

Earnings Snapshot & Headline Estimates

• Consensus Revenue Estimate: ~$16.33 billion to $16.35 billion (representing ~2%–4% YoY growth).

• Consensus EPS Estimate: Loss of ($0.26) per share. Note on Earnings: The headline EPS reflects the impact of a ~$5.8 billion (~$2.35/share) upfront charge associated with Merck's acquisition of Terns Pharmaceuticals, which closed in May 2026.

• Full-Year 2026 Guidance: Prior FY26 adjusted EPS guidance was $5.04–$5.16. Investors will watch for updates reflecting recent M&A accounting adjustments.

Merck & Co. (MRK) reported fiscal Q1 2026 results that beat top- and bottom-line Wall Street expectations. Despite reporting a net loss due to a large upfront acquisition charge, core underlying growth was propelled by strong oncology performance and rapid adoption of newly launched therapies.

Key Portfolio & Segment Drivers

1. Keytruda & Keytruda QLEX (Subcutaneous)

• Performance: Generated $8.0 billion in total sales (+12% YoY, +8% ex-FX).

• Key Highlight: The newly launched subcutaneous formulation (Keytruda QLEX) recorded $128 million in its inaugural quarter, supported by receiving its permanent J-code on April 1, 2026.

• Wholesaler Timing Note: U.S. sales included an approximate ~$250 million timing benefit from wholesaler inventory purchases, which management explicitly noted will reverse as a headwind in Q3 2026.

2. Commercial Launch Standout: Winrevair

• Generated $525 million (+88% YoY), solidifying its role as Merck's primary growth engine in pulmonary arterial hypertension (PAH).

3. Drag Area: Gardasil / Gardasil 9

• Sales: $1.07 billion to $1.10 billion (down 19%–22% YoY).

• Drivers: Sluggish consumer demand and inventory adjustments in international markets—predominantly China and Japan—along with CDC order timing in the U.S.

Full-Year 2026 Guidance Update

Merck raised and narrowed its FY 2026 guidance range following the Q1 performance:

• Full-Year Revenue: Raised to $65.8 billion – $67.0 billion (up from prior $65.5B–$67.0B), representing 1%–3% YoY growth.

• Full-Year Adjusted EPS: Raised to $5.04 – $5.16 (up from prior $5.00–$5.15).

• Note on M&A Exclusion: This guidance includes a ~$0.10 FX tailwind but excludes the pending $5.8 billion (~$2.35/share) upfront R&D charge from the Terns Pharmaceuticals acquisition expected to close later in 2026.

4 Lessons Learned from Merck's Q1 Guidance & Commentary

1. Separate M&A Accounting Spikes from Operational Strength

Large upfront Acquired In-Process Research and Development (AIPRD) charges—such as the $3.62 per share Cidara charge in Q1 and the upcoming $2.35 per share Terns charge—frequently drive GAAP EPS into negative territory. Investors must insulate core operating cash flow and adjusted earnings from one-time strategic pipeline acquisitions.

2. The Subcutaneous Transition Is Essential Ahead of 2028

Keytruda’s patent expiration (~2028) remains Merck’s primary long-term overhang. The early adoption of Keytruda QLEX ($128M) and permanent J-code assignment demonstrate that Merck’s strategy to convert intravenous patients to subcutaneous delivery is gaining early traction.

3. Account for Inventory Reversals Across Quarters

Management's transparent disclosure of a ~$250 million U.S. Keytruda inventory pull-forward means Q2 and Q3 revenues may show artificial quarter-over-quarter lumpiness. Evaluating 12-month rolling trends rather than single-quarter beats prevents misinterpreting distributor inventory swings as shift in underlying patient demand.

4. Launch Success (Winrevair) Is Active Defense Against Regional Headwinds

Gardasil's multi-quarter weakness in China highlights regional vaccine demand volatility. However, the strong ramp of Winrevair ($525M) and specialty oncology therapies (Welireg, Capvaxive) shows that Merck's commercial pipeline is expanding fast enough to absorb regional segment headwinds without degrading full-year revenue targets.

Key Metrics & Segments to Watch

A. Keytruda (PD-1 Inhibitor)

• Consensus Target: ~$8.06 billion.

• What to Watch: Keytruda remains Merck’s top top-line engine. Key performance indicators include market share gains in earlier-stage oncology indications (adjuvant/neoadjuvant settings) vs. metastatic indications, as well as subcutaneous formulation progress ahead of its 2028 patent cliff.

B. Launch & Growth Portfolio

• Winrevair (sotatercept): Critical commercial ramp for pulmonary arterial hypertension (PAH). Sequentially higher adoption here serves as early validation of Merck’s post-Keytruda growth engine.

• Welireg & Capvaxive: Revenue contribution from new specialty oncology and pneumococcal vaccine launches.

C. Vaccines & Legacy Portfolio Drag

• Gardasil / Gardasil 9: Monitor demand dynamics in international markets (particularly China) and any inventory rebalancing that pulled down sales in prior periods.

• Specialty & Hospital Products: Watch for generic erosion in ex-U.S. markets on products like Bridion offset by domestic U.S. demand.

3. Strategic Narrative & M&A Pipeline

1. Pipeline Diversification: Merck continues to deploy capital aggressively to offset Keytruda's loss of exclusivity (LOE) expected around 2028.

2. Business Development (BD) Costs: Focus on management's commentary regarding the integration of Terns Pharmaceuticals and pipeline clinical milestones expected in H2 2026.

Merck (MRK) Price Target

Based on 18 Wall Street analysts offering 12 month price targets for Merck & Company in the last 3 months. The average price target is $136.94 with a high forecast of $155.00 and a low forecast of $100.00. The average price target represents a 5.18% change from the last price of $130.20.

Post-Earnings Short-Term Trading Analysis

Option Volatility Mechanics

• Implied Volatility (IV) Crush: Option premiums tend to spike immediately prior to earnings and compress sharply (IV crush) right after the press release and earnings call.

• Historical Move: MRK typically moves between 2.5% and 4.0% post-earnings.

Strategic Options Ideas (Post-Release)

Summary

Merck & Co. (MRK) reports its fiscal Q2 2026 financial results on Tuesday, August 4, 2026, before the market opens. Wall Street consensus projects worldwide sales between $16.33 billion and $16.35 billion (representing 2%–4% YoY growth) and a headline EPS loss of ($0.26) per share. The per-share loss reflects a ~$5.8 billion (~$2.35/share) upfront Acquired In-Process R&D (AIPRD) charge tied to the acquisition of Terns Pharmaceuticals, which closed in May 2026.

Primary Metrics to Watch

• Keytruda Franchise (~$8.06B consensus): Focus remains on adoption in earlier-stage oncology settings and patient migration to the subcutaneous formulation (Keytruda QLEX) ahead of the 2028 patent cliff.

• Commercial Growth Engine (Winrevair): Adoption metrics for Winrevair (sotatercept) in pulmonary arterial hypertension serve as a vital indicator of Merck’s ability to replace key exclusivity losses.

• Gardasil Headwinds: Investors will watch for stabilizing end-market demand in international regions—particularly China and Japan—following multi-quarter inventory rebalancing.

Short-Term Post-Earnings Trading Opportunities

Historical post-earnings price reactions for MRK typically span 2.5% to 4.0%. Because options implied volatility (IV) spikes into the release and drops sharply afterward (IV crush), traders often look at:

1. Credit Spreads / Iron Condors: Selling OTM Bull Put Spreads or Iron Condors post-release to capture elevated volatility collapse if support levels hold.

2. Directional Momentum: Waiting 15–30 minutes past the 9:00 AM ET investor call to trade confirmed breakout or breakdown moves using defined-risk vertical spreads.

Appreciate if you could share your thoughts in the comment section whether you think MRK earnings would continue to help earnings to keep August bullish momentum.

@TigerStars @Daily_Discussion @Tiger_Earnings @TigerWire @MillionaireTiger appreciate if you could feature this article so that fellow tiger would benefit from my investing and trading thoughts.

Disclaimer: The analysis and result presented does not recommend or suggest any investing in the said stock. This is purely for Analysis.